CBAY
Cymabay Therapeutics Inc (CBAY)
$3.9516.86%▲
Market is closedMarket is closed – opens on 8 PM, 02 Dec 2022
– opens on 8 PM, 02 Dec 2022
Key Stats
$3.3739
Day's Range
$4.0012
$1.67
52-Week Range
$4.3
| Returns | |
| 1 month return | 13.51% |
| 3 month return | 12.86% |
| 1 year return | 17.56% |
| 5 year return | 53.47% |
Company Information
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently commencing a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC.
| Organization | Cymabay Therapeutics Inc |
| Employees | 59 |
| CEO | Mr. Sujal A. Shah |
| Industry | Health Technology |
Analyst Recommendation
based on 9 analysts ratings
Buy
100%
Buy
0%
Hold
0%
Sell
Based on 9 Wall street analysts offering stock ratings for Cymabay Therapeutics Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 153.16%Current
$3.95
Target
$10.0
Recommendation Trend
Based on 9 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 9 | 14 | 13 |
| Hold | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Highlights
| Market Capitalization | 286.2M |
| Book Value | $0.71 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.32 |
| PEG Ratio | 0.0 |
| Wall Street Target Price | 10.0 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 4.64 |
| Enterprise Value | 213.0M |
| Enterprise Value/Revenue | 0.0 |
| Enterprise Value/Ebitda | -2.31 |
Technicals
| Beta | 0.54 |
| 50 Day MA | 3.41 |
| 200 Day MA | 3.11 |
Institutional Holdings
venBio Select Advisor LLC
12.16%
TCG Crossover Management, LLC
6.97%
COMMODORE CAPITAL LP
6.78%
Vanguard Group Inc
4.33%
Millennium Management LLC
3.56%
Nantahala Capital Management, LLC
3.12%
Discover more
Frequently Asked Questions
What is Cymabay Therapeutics Inc share price today?
Can Indians buy Cymabay Therapeutics Inc shares?
How can I buy Cymabay Therapeutics Inc shares from India?
Can Fractional shares of Cymabay Therapeutics Inc be purchased?
What are the documents required to start investing in Cymabay Therapeutics Inc stocks?
What are today’s High and Low prices of Cymabay Therapeutics Inc?
What are today’s traded volumes of Cymabay Therapeutics Inc?
What is today’s market capitalisation of Cymabay Therapeutics Inc?
What is the 52 Week High and Low Range of Cymabay Therapeutics Inc?
How much percentage Cymabay Therapeutics Inc is down from its 52 Week High?
How much percentage Cymabay Therapeutics Inc is up from its 52 Week low?
What are the historical returns of Cymabay Therapeutics Inc?
Who is the Chief Executive Officer (CEO) of Cymabay Therapeutics Inc?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*